{
  "url": "https://www.law.cornell.edu/regulations/new-york/10-NYCRR-80.63",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 10 § 80.63 - Prescribing",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 10 § 80.63 - Prescribing\n\nState Regulations\n(a) A prescription as defined by the Public\n\nHealth Law means: (1)\nan official New York\n\nState prescription; (2)\nan\nelectronic prescription; (3)\nan\noral prescription; or\n(4)\nan\nout-of-state prescription, which means a prescription issued in lieu of an\nofficial prescription by a practitioner in another state who is licensed by\nthat state to prescribe controlled substances. (b) The use of preprinted prescriptions which\nindicate the controlled substance or the strength, dosage and/or quantity of\nthe controlled substance is prohibited. Such prohibition shall not apply to\nprinted prescriptions generated by means of a computer or an electronic medical\nrecord system, provided such printed prescriptions are generated at the time a\npractitioner prescribes a controlled substance for a patient. (c) (1)\n\nPrior to prescribing for or dispensing to a patient any controlled substance\nlisted on schedule II, III, or IV of section\n3306\nof the\n\nPublic Health Law, every practitioner shall consult the prescription monitoring\nprogram registry for the purpose of reviewing that patient's controlled\nsubstance history. The patient's controlled substance history shall be obtained\nfrom the prescription monitoring program registry no more than 24 hours prior\nto the practitioner prescribing or dispensing any controlled substance to that\npatient. A practitioner shall document such consultation in the patient's\nmedical chart or, if the practitioner does not consult the prescription\nmonitoring program registry, the practitioner shall document in the patient's\nmedical chart the reason such consultation was not performed. Such\ndocumentation shall include the specific exception listed in paragraph (2) of\nthis subdivision. (i) When such consultation\nis not performed due to circumstances specified in subparagraph (2)(vii) of\nthis subdivision, the practitioner shall further document in the patient's\nmedical chart the conditions, occurrences, or circumstances that caused such\nconsultation in a timely manner to be unreasonable. Such documentation shall\ninclude a description of the barrier(s) to accessing the registry, and the\nefforts made by the practitioner to contact other designees. (ii)\n\nWhen such consultation is not performed\ndue to circumstances specified in subparagraph (2)(viii) of this subdivision, the practitioner shall further document in the patient's medical chart a\ndescription of the circumstances supporting the practitioner's conclusion that\nconsultation of the registry would adversely impact the patient's ability to\nobtain a prescription in a timely manner and the relationship between that\ndelay and the patient's medical condition. (2)\n\nThe duty to consult the prescription\nmonitoring program registry shall not apply to: (i) veterinarians; (ii)\na practitioner dispensing pursuant to\n\nPublic Health Law section 3351(3); (iii)\na practitioner administering a\ncontrolled substance, as defined in Public Health Law section\n3302(2); (iv)\na practitioner\nprescribing or ordering a controlled substance pursuant to Public Health Law\nsection 3342(1) for a patient of an institutional dispenser as defined by\n\nPublic Health Law section 3302 for use on the premises of, or during an\nemergency transfer from, the institutional dispenser; (v) a practitioner prescribing a controlled\nsubstance in the emergency department of a general hospital, provided that the\nquantity of controlled substance prescribed does not exceed a five-day supply\nif the controlled substance were used in accordance with the directions for\nuse; (vi)\na practitioner\nprescribing a controlled substance to a patient under the care of a hospice, as\ndefined by Public Health Law section 4002; (vii)\na practitioner when: (a) it is not reasonably possible for the\npractitioner to access the registry in a timely manner; (b) no other practitioner or designee\nauthorized to access the registry, pursuant to Public Health Law section\n3343-a, is reasonably available; and\n(c) the quantity of controlled substance\nprescribed does not exceed a five-day supply if the controlled substance were\nused in accordance with the directions for use; (viii)\na practitioner acting in circumstances\nunder which consultation of the registry would, as determined by the\npractitioner, result in a patient's inability to obtain a prescription in a\ntimely manner, thereby adversely impacting the medical condition of such\npatient, provided that the quantity of the controlled substance does not exceed\na five-day supply if the controlled substance were used in accordance with the\ndirections for use; (ix)\na\nsituation where the registry is not operational as determined by the department\nor where it cannot be accessed by the practitioner due to a temporary\ntechnological or electrical failure as defined in section\n80.64\nof this Part. In the\ninstance of a temporary technological or electrical failure, a practitioner\nshall, without undue delay, seek to correct any cause for the failure that is\nreasonably within his or her control; or\n(x) a practitioner to whom the commissioner\nhas granted a waiver from the requirement to consult the registry. A waiver may\nbe issued by the commissioner based upon a showing by a practitioner that his\nor her ability to consult the registry in accordance with this section is\nunduly burdened by: (a) technological\nlimitations that are not reasonably within the control of the practitioner; or\n(b) other exceptional\ncircumstance demonstrated by the practitioner. The practitioner's showing shall include a sworn\nstatement of facts detailing the circumstances in support of a waiver, and\nshould be accompanied by any and all other information which would be relevant\nto the commissioner's determination. As part of the application for a waiver, the practitioner shall also provide any information which would tend to negate\nthe need for a waiver. A waiver shall be granted by the commissioner for a\nspecified period of time, but in no event for more than one year. Subsequent\nwaivers shall be applied for in the same manner and shall be subject to the\nsame requirements as the original waiver. A practitioner who has been granted a\nwaiver shall notify the department in writing within five business days upon\ngaining the capability to consult the prescription monitoring program registry. Without regard to the original expiration date, the waiver granted to the\npractitioner shall terminate within a reasonable period of time as determined\nby the department, allowing for the practitioner to make accommodations to\nbegin consulting the prescription monitoring program registry. (3)\nA\npractitioner may authorize a designee to consult the prescription monitoring\nprogram registry on his or her behalf, provided that the ultimate decision as\nto whether or not to prescribe or dispense a controlled substance remains with\nthe practitioner and is reasonably informed by the relevant controlled\nsubstance history information obtained from the registry. A practitioner may\nonly appoint a designee if: (i) such designee\nis located in the State of New York when accessing the prescription monitoring\nprogram registry; (ii)\nthe designee\nis employed by the same professional practice or is under contract with such\npractice. For purposes of this subparagraph, professional practice shall\ninclude, but not be limited to, an institutional dispenser where the\ndesignating practitioner is employed, under contract, or otherwise has\nprivileges or authorization to practice; (iii)\nthe practitioner takes reasonable steps\nto ensure or has actual knowledge that such designee is sufficiently competent\nin the use of the registry and that such designee is aware of and conforms to\nall relevant Federal and State privacy statutes; (iv)\nthe practitioner remains responsible for\nensuring that access to the registry by the designee is limited to authorized\npurposes and occurs in a manner that protects the confidentiality of the\ninformation obtained from the registry, and the practitioner remains\nresponsible for any breach of confidentiality; and\n(v) the practitioner selects and maintains\nall active designees authorized to access the prescription monitoring program\nregistry in a format acceptable to the department. Upon a designee's\nrelinquishment or termination of employment or authorization as a designee, a\ndesignating practitioner shall immediately notify the department, in a fashion\ndeemed appropriate by the commissioner, of the revocation of the designee's\nauthorization to access the prescription monitoring program registry on the\ndesignating practitioner's behalf. (4)\nA pharmacist may consult the prescription\nmonitoring program registry in order to review the controlled substance history\nof an individual for whom one or more prescriptions for controlled substances\nis presented to such pharmacist. A pharmacist may designate another pharmacist\nor a pharmacy intern as defined by section\n6806\nof the\n\nEducation Law to consult the prescription monitoring program registry on the\npharmacist's behalf, provided that: (i) such\ndesignee is located in the State of New York when accessing the prescription\nmonitoring program registry and is employed by the same pharmacy or is under\ncontract with such pharmacy; and\n(ii)\nthe designating pharmacist selects and\nmaintains all active designees authorized to access the prescription monitoring\nprogram registry in a format acceptable to the department. Upon relinquishment\nor termination of employment or authorization as a designee, a designating\npharmacist shall immediately notify the department, in a fashion deemed\nappropriate by the commissioner, of the revocation of the designee's\nauthorization to access the prescription monitoring program registry on the\ndesignating pharmacist's behalf. (d) No controlled substance shall be\nprescribed prior to an in-person medical evaluation of the patient by the\nprescribing practitioner for the medical condition for which the controlled\nsubstance is being considered. The practitioner shall determine the parameters\nfor the medical evaluation, and frequency of future medical evaluations as part\nof the patient's continuing treatment, utilizing generally accepted medical\nstandards and taking into account the drug to be prescribed and the patient's\nmedical condition, history and disposition toward the use of controlled\nsubstances. (e) Notwithstanding\nsubdivision (d) of this section, a controlled substance may be prescribed by a\npractitioner, in the absence of the practitioner performing an in-person\nmedical evaluation, in the following circumstances: (1)\nwhen utilizing a consulting or referring\npractitioner - for their patient after review of the patient's record if the\nrecord contains the result of an in-person medical evaluation performed by a\nconsulting or referring practitioner within the previous 12 months specific to\nthe medical condition for which the prescription is being considered. (2)\nfor a covering practitioner - in the\ntemporary absence of the initial prescriber for a patient as part of a\ncontinuing therapy, provided the prescribing practitioner either: (i) is part of the same practice as the\ninitial prescriber and has direct access to the patient's medical records, and\nsuch records warrant continued controlled substance prescribing, or\n(ii)\nhas direct and adequate consultation\nwith the initial prescriber, who assures the necessity of continued controlled\nsubstance prescribing and with which the practitioner concurs. If the patient\nrecord is not available, the practitioner shall document the activity for their\nown record and shall transmit to the initial prescriber the prescription\ninformation within 72 hours. The initial prescriber shall include the\nprescription information in the patient's record. (3)\nfor a new condition in an emergency\nsituation - if a patient develops a new medical condition that would warrant\nthe issuance of a prescription for a controlled substance, provided that: (i) the prescribing practitioner has a\npreviously established practitioner/patient relationship with the\npatient; (ii)\nan emergency exists\nsuch that the immediate administration of the drug is necessary for the proper\ntreatment of the patient and no alternative treatment is available; and\n(iii)\nthe prescription does not\nexceed a 5-day supply as determined by the directions for use. If the\npractitioner prescribes such substance orally, the practitioner must comply\nwith the requirements of section\n80.68\nand section\n80.70\nof this\n\nPart. (4)\nthrough\ntelemedicine or telehealth - as such terms are defined by article 29-G of the\n\nPublic Health Law, consistent with all applicable state laws and regulations\nand the laws, rules and regulations of the Drug Enforcement Administration, United States Department of Justice, or any successor agency. This is inclusive\nof any controlled substance as approved by the Food and Drug Administration\n(FDA), or its successor agency, and the New York State Department of Health for\nthe treatment of opioid use disorder as listed in section\n80.84\nof this\n\nPart. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 10\n§\n80.63\n\nAmended\n\nNew\n\nYork State Register May 21, 2025/Volume XLVII, Issue 20, eff. 5/21/2025\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. (a) A prescription as defined by the Public Health Law means: (1)\nan official New York\n\nState\nprescription; (2)\nan electronic prescription; (3)\nan oral prescription; or\n(4)\nan out-of-\nstate\nprescription, which means a prescription issued in lieu of an official prescription by a practitioner in another\nstate\nwho is licensed by that\nstate\nto prescribe controlled substances. (b) The\nuse\nof preprinted prescriptions which indicate the controlled substance or the strength, dosage and/or quantity of the controlled substance is prohibited. Such prohibition shall not apply to printed prescriptions generated by means of a computer or an electronic medical record system, provided such printed prescriptions are generated at the time a practitioner prescribes a controlled substance for a patient. (c) (1)\n\nPrior to prescribing for or dispensing to a patient any controlled substance listed on schedule II, III, or IV of section\n3306\nof the Public Health Law, every practitioner shall consult the prescription\nmonitoring\nprogram registry for the purpose of reviewing that patient's controlled substance history. The patient's controlled substance history shall be obtained from the prescription\nmonitoring\nprogram registry no more than 24 hours prior to the practitioner prescribing or dispensing any controlled substance to that patient. A practitioner shall document such consultation in the patient's medical chart or, if the practitioner does not consult the prescription\nmonitoring\nprogram registry, the practitioner shall document in the patient's medical chart the reason such consultation was not performed. Such documentation shall include the specific exception listed in paragraph (2) of this subdivision. (i) When such consultation is not performed due to circumstances specified in subparagraph (2)(vii) of this subdivision, the practitioner shall further document in the patient's medical chart the conditions, occurrences, or circumstances that caused such consultation in a timely manner to be unreasonable. Such documentation shall include a description of the barrier(s) to accessing the registry, and the efforts made by the practitioner to contact other designees. (ii)\n\nWhen such consultation is not performed due to circumstances specified in subparagraph (2)(viii) of this subdivision, the practitioner shall further document in the patient's medical chart a description of the circumstances supporting the practitioner's conclusion that consultation of the registry would adversely impact the patient's ability to obtain a prescription in a timely manner and the relationship between that delay and the patient's medical condition. (2)\n\nThe duty to consult the prescription\nmonitoring\nprogram registry shall not apply to: (i) veterinarians; (ii)\na practitioner dispensing pursuant to Public Health Law section 3351(3); (iii)\na practitioner administering a controlled substance, as defined in Public Health Law section 3302(2); (iv)\na practitioner prescribing or ordering a controlled substance pursuant to Public Health Law section 3342(1) for a patient of an institutional dispenser as defined by Public Health Law section 3302 for\nuse\non the premises of, or during an emergency transfer from, the institutional dispenser; (v) a practitioner prescribing a controlled substance in the emergency\ndepartment\nof a general hospital, provided that the quantity of controlled substance prescribed does not exceed a five-day supply if the controlled substance were used in accordance with the directions for\nuse; (vi)\na practitioner prescribing a controlled substance to a patient under the care of a hospice, as defined by Public Health Law section 4002; (vii)\na practitioner when: (a) it is not reasonably possible for the practitioner to access the registry in a timely manner; (b) no other practitioner or designee authorized to access the registry, pursuant to Public Health Law section 3343-a, is reasonably available; and\n(c) the quantity of controlled substance prescribed does not exceed a five-day supply if the controlled substance were used in accordance with the directions for\nuse; (viii)\na practitioner acting in circumstances under which consultation of the registry would, as determined by the practitioner, result in a patient's inability to obtain a prescription in a timely manner, thereby adversely impacting the medical condition of such patient, provided that the quantity of the controlled substance does not exceed a five-day supply if the controlled substance were used in accordance with the directions for\nuse; (ix)\na situation where the registry is not operational as determined by the\ndepartment\nor where it cannot be accessed by the practitioner due to a temporary technological or electrical failure as defined in section\n80.64\nof this Part. In the instance of a temporary technological or electrical failure, a practitioner shall, without undue delay, seek to correct any cause for the failure that is reasonably within his or her control; or\n(x) a practitioner to whom the\ncommissioner\nhas granted a waiver from the requirement to consult the registry. A waiver may be issued by the\ncommissioner\nbased upon a showing by a practitioner that his or her ability to consult the registry in accordance with this section is unduly burdened by: (a) technological limitations that are not reasonably within the control of the practitioner; or\n(b) other exceptional circumstance demonstrated by the practitioner. The practitioner's showing shall include a sworn statement of facts detailing the circumstances in support of a waiver, and should be accompanied by any and all other information which would be relevant to the\ncommissioner\n's determination. As part of the application for a waiver, the practitioner shall also provide any information which would tend to negate the need for a waiver. A waiver shall be granted by the\ncommissioner\nfor a specified period of time, but in no event for more than one\nyear. Subsequent waivers shall be applied for in the same manner and shall be subject to the same requirements as the original waiver. A practitioner who has been granted a waiver shall notify the\ndepartment\nin writing within five business days upon gaining the capability to consult the prescription\nmonitoring\nprogram registry. Without regard to the original expiration date, the waiver granted to the practitioner shall terminate within a reasonable period of time as determined by the\ndepartment, allowing for the practitioner to make accommodations to begin consulting the prescription\nmonitoring\nprogram registry. (3)\nA practitioner may authorize a designee to consult the prescription\nmonitoring\nprogram registry on his or her behalf, provided that the ultimate decision as to whether or not to prescribe or dispense a controlled substance remains with the practitioner and is reasonably informed by the relevant controlled substance history information obtained from the registry. A practitioner may only appoint a designee if: (i) such designee is located in the\n\nState\nof New York when accessing the prescription\nmonitoring\nprogram registry; (ii)\nthe designee is employed by the same\nprofessional practice\nor is under contract with such practice. For purposes of this subparagraph, professional practice\nshall include, but not be limited to, an institutional dispenser where the designating practitioner is employed, under contract, or otherwise has privileges or authorization to practice; (iii)\nthe practitioner takes reasonable steps to ensure or has actual knowledge that such designee is sufficiently competent in the\nuse\nof the registry and that such designee is aware of and conforms to all relevant Federal and\n\nState\nprivacy statutes; (iv)\nthe practitioner remains responsible for ensuring that access to the registry by the designee is limited to authorized purposes and occurs in a manner that protects the confidentiality of the information obtained from the registry, and the practitioner remains responsible for any breach of confidentiality; and\n(v) the practitioner selects and maintains all active designees authorized to access the prescription\nmonitoring\nprogram registry in a format acceptable to the\ndepartment. Upon a designee's relinquishment or termination of employment or authorization as a designee, a designating practitioner shall immediately notify the\ndepartment, in a fashion deemed appropriate by the\ncommissioner, of the revocation of the designee's authorization to access the prescription\nmonitoring\nprogram registry on the designating practitioner's behalf. (4)\nA pharmacist may consult the prescription\nmonitoring\nprogram registry in order to review the controlled substance history of an\nindividual\nfor whom one or more prescriptions for controlled substances is presented to such pharmacist. A pharmacist may designate another pharmacist or a pharmacy intern as defined by section\n6806\nof the Education Law to consult the prescription\nmonitoring\nprogram registry on the pharmacist's behalf, provided that: (i) such designee is located in the\n\nState\nof New York when accessing the prescription\nmonitoring\nprogram registry and is employed by the same pharmacy or is under contract with such pharmacy; and\n(ii)\nthe designating pharmacist selects and maintains all active designees authorized to access the prescription\nmonitoring\nprogram registry in a format acceptable to the\ndepartment. Upon relinquishment or termination of employment or authorization as a designee, a designating pharmacist shall immediately notify the\ndepartment, in a fashion deemed appropriate by the\ncommissioner, of the revocation of the designee's authorization to access the prescription\nmonitoring\nprogram registry on the designating pharmacist's behalf. (d) (1)\n\nNo controlled substance prescription shall be issued prior to examination of the patient by the practitioner except as otherwise permitted by this subdivision. (2)\n\nOnce the initial examination has been completed, the frequency and necessity for future examinations prior to prescribing, either for the same acute or chronic condition, will be made by the practitioner utilizing generally accepted medical standards, including taking into account the drug to be prescribed and the patient's condition, history and disposition toward the\nuse\nof controlled substances. (3)\n\nIn the temporary absence of the initial prescriber, an authorized practitioner may issue a controlled substance prescription for a patient as part of a continuing therapy if the practitioner: (i) had direct access to the patient's medical records and such records warrant continued controlled substance prescribing; or\n(ii)\nhad direct and adequate consultation with the initial prescriber, who assures the necessity of continued controlled substance prescribing and with which the practitioner concurs. If the patient record is not available, the practitioner shall document the\nactivity\nfor his or her own record and shall transmit to the initial prescriber the prescription information. The initial prescriber shall include the prescription information in the patient's record. (4)\nA practitioner may prescribe a controlled substance to his or her patient after review of the patient's record if the record contains the result of an examination performed by a consulting physician or hospital and such record warrants the prescribing. (5)\n\nIf a patient develops a new condition that would warrant the issuance of a prescription for a controlled substance, a practitioner may issue such prescription prior to performing an examination if: (i) the prescribing practitioner has a previously established practitioner/patient relationship with the patient; (ii)\nan emergency exists; and\n(iii)\nthe prescription does not exceed a five day supply as determined by the directions for\nuse. An emergency means that the immediate administration of the drug is necessary for the proper treatment of the patient and that no alternative treatment is available. If the practitioner prescribes such substance orally, the practitioner must comply with the requirements of sections 80.68 and\n80.70\nof this Part. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 10\n§\n80.63",
  "url_type": "regulation",
  "source_index": 22451
}